Comera Life Sciences Debuts in the Red

by | May 20, 2022

The maker of self-injectible biologics closed down 9% on the day. An updated look at deSPAC count and redemption rates.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Comera Life Sciences (CMRA) deSPACs today

Self-ingestible biologics specialist Comera Life Sciences CMRA) deSPAC’d today from OTR Acquisition Corp (OTRA). Low float deSPAC: 9.8M shares redeemed (94%). Shares closed at $8.85, down 9%.

deSPAC Count and Redemption Update

As we prepare for the last week of May, here’s an update on deSPAC and redemption stats. In addition to CMRA, three other SPACs have made it out: Eve (EVEX), NuScale Power (SMR), and SAITECH (SAI). All are trading below $10. Redemptions look like they are trending back up: average redemption rate is 75% month-to-date–down from 74% in April and 29% in the year ago.

Source: Boardroom Alpha

deSPAC Heat Map

Shares of the Southeast Asian delivery, mobility and financial services app Grab Holdings (GRAB) are showing strong momentum, jumping 24% yesterday on the company’s earnings upside and upward revision to guidance. Urban air mobility specialist Eve Holding (EVEX) is another upward mover, having been volatile since its deSPAC on May 10th. Shares closed up 6% today.

Source: Boardroom Alpha

Elsewhere in SPACs

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.